Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership
By Will Feuer
Bristol Myers Squibb will take a stake in Avidity Biosciences as part of a broader licensing and research deal focused on the development and commercialization of multiple cardiovascular targets.
Bristol will pay Avidity $60 million in cash and buy about $40 million of its stock at a price of $7.88 a share as part of the deal.
Avidity could earn up to about $1.35 billion in research and development milestone payments, and up to about $825 million in commercial milestone payments. Avidity also will be eligible for tiered royalties of up to a low double-digit percentage of net sales. Bristol will fund all clinical development, regulatory and commercialization activities tied to the collaboration.
Avidity is working on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics.
The new deal with Bristol expands a 2021 research pact that Avidity struck with MyoKardia, a Bristol subsidiary, to explore the potential use of AOCs in cardiac tissue.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
November 28, 2023 07:06 ET (12:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks